



Clificol COVID-19 Support Project

9 Mar 2021

Medical Disclaimer

- Homeopathy is a patient-centered approach that does not directly target the COVID-19 virus.
- Instead, homeopathy aims to enhance the patient's own ability to fight and recover from an infection.
- Homeopaths have a long experience (more than 200 years) with the treatment of epidemic diseases, often with promising results.
- The effectiveness of homeopathy in COVID-19 patients is currently unknown.
- Therefore, homeopaths are systematically collecting and analyzing their experiences with the treatment of COVID-19 patients.
- Given the scarcity of therapeutic treatment options for COVID-19, investigating how complementary approaches could contribute, is justified.
- Subject to further confirmation / research, homeopathy may play a role as an **adjunct** to conventional treatment and offer advice in the management of COVID-19.

Clifical COVID-19 Support Project

Online Case Registry

Homeopathy for Covid?

- Chance effects (Control group)
- Confounders
- Other biases

➡ NOT PROVING EFFECTIVENESS OF HOMEOPATHY **WITHIN** THIS STUDY

Causality in the context of homeopathic treatment

The predictability of the effect of homeopathic prescriptions provides evidence that homeopathic prescriptions and the subsequent case evolution are not a **RANDOM** phenomenon **IMAGINED** by homeopaths.

Main Research Questions


- What are the most commonly prescribed remedies?
- Is there any particular and distinct symptomatic presentations in COVID-19 patients? (INDIVIDUALIZATION?)
- Do homeopathic symptom pictures correlate with successful homeopathic prescriptions of a corresponding remedy in COVID-19 patients? (LAW OF SIMILARS?)
- Are symptom pictures associated with factors other than geographical such as age, sex, comorbidities, diagnosis accuracy

Main Research Questions


- Is there evidence to support the notion of 'Genus Epidemicus' (one core set of symptoms corresponding to one remedy per geographic location)?
- What are the key differentiating factors between the different symptom/remedy pictures?
- What is the observed progression in severity of symptoms?
- Are unexpected side effects observed or safety concerns reported?

Data Reporting (03/02/2021)

- ◆ 840 cases
- ◆ 2340 consultations
- ◆ 1138 prescriptions
- ◆ 46% of prescriptions have no associated rubrics




Time course dependent
on country




Demographics

- ◆ Female 54%
- ◆ Mean Age: 40.6 ± 15.3 year old
- ◆ Minimum: 0-year-old
- ◆ Maximum: 100-year-old



Countries:

China 295
India 186
United States 156
France 44
Italy 35
Spain 17
Belgium 17
Argentina 14
Netherlands 12
United Kingdom 9
Romania 7
Turkey 6
Austria 6
Canada 5
Germany 5
Slovenia 4
Iceland 3
Afghanistan 3
Albania 3
Hong Kong 2
Angola 2
Brazil 1
Belarus 1
Algeria 1
Antarctica 1
Falkland Islands (Malvinas) 1
Swiss 1
Mexico 1
Ireland 1
Slovakia 1







Severity at First Consultation

	Count	Percent
1 - Mild	755	90%
2 - Moderate	70	8%
3 - Severe	12	1.4%
4 - Critical	3	0.3%
5 - Very Critical	0	0%
Total	840	100%



Q1:What are the most
commonly prescribed
remedies?






Q2: Is there any difference in symptomatic presentation among COVID-19 cases?

INDIVIDUALIZED
TREATMENT

Cluster Analysis

Looking for groups
with common
features



Q3: Do homeopathic symptom patterns correlate with successful homeopathic prescriptions of a corresponding remedy in COVID-19 patients?

LAW OF SIMILARS

Gelsemium as an example

(Preliminary analysis from data in July)

Fast recovery (with relative faster recovery within this Clificol database)

= improvement in day 1 and day 3 outcome assessment, with no relapse at day 7.

Slow recovery = Fail to meet the above criteria, or success of other remedies.

Logistic Modelling Selection

(Backward, Likelihood test = Drop-in-deviance test)

	Beta	Adjusted OR (95%CI)	P-value
Age	-0.034	0.97 (0.92 – 1.02)	0.22
MIND - DULLNESS	1.628	5.10 (0.94 – 27.61)	0.06
EYE - HEAVINESS - Lids	1.644	5.17 (0.75 – 35.80)	0.10
STOMACH - THIRSTLESS	1.799	6.05 (0.79 – 46.21)	0.08
COUGH - NIGHT	2.438	11.46 (0.52 – 250.9)	0.12
HEAD - PAIN - urination - profuse - amel.	3.704	40.62 (4.30 – 383.35)	0.001

The best model for Gelsemium with the current sample size:

- ◇ For a COVID-19 patient **aged 30**, presented with **Dullness**, **heaviness of eyelids**, **thirst**, **cough agg. at night**, and **no headache amel** from profuse urination.
- ◇ π is the probability of fast-recovery from Gelsemium
- ◇ $\log \left(\frac{p}{1-p} \right) = -2.709 - 0.034 * \text{Age} + 1.628 * \text{Dull} + 1.644 * \text{Lid} + 1.799 * \text{thirstless} + 2.438 * \text{Coughnight} + 3.704 * \text{profuseamel}$
- ◇ $p = 88.0\%$

When sample size is large enough.....

- ◆ Models can be built for each commonly used remedy
- ◆ Will be a mathematical proof for 'Law of Similars'
- ◆ Can investigate the concepts of 'Keynote', 'SRP symptoms', 'three-leg stool', and so on.



Clificol 2020+ webinars

(English, Spanish, German,
Portuguese, Italian)

Register for FREE:

<https://clificol.net/en/upcoming-webinars>

You may receive our invitation
in the next round!

Co-authoring policies?



Dr. Farokh Master

**Management of COVID
patients in the ICU**

11/Mar (Thurs)
CET 3:30pm / EST 9:30am /
India time 8pm



**Dr. Raj Manchanda
& his team**

**Experience sharing of the
COVID management in the
public sector in India**

18/Mar (Thurs)
Indian time 5pm /
CET 12:30 noon / EDT 7:30am

Experience sharing in other webinars by:

Anna Gerstenhöfer (GER), Frederik Schroyens (GER/ENG), Hélène Renoux (ENG), Clapers Marc Lluís (SPA), Denise Straiges (ENG), Francis Mourao (Port)



Useful links

- ◆ Brief introduction of the clificol covid-19 support project (10 min)
- ◆ <https://www.youtube.com/watch?v=xWIG06dfQeU>
- ◆ How to submit a case in 7 minutes
- ◆ <https://www.youtube.com/watch?v=PpmRNo2PgZU>

Acknowledgement

- With the support of **ECH, ECCH, ICH, HRI, LMHI**, and other professional associations, Governance Committee now consists of 11 representatives, representing **197 associations**
- More than 35 **national coordinators** are now working together for the qualification verification
- **Scientific Committee** consists of research experts coming from all over the world
- Special thanks to **Zeus-soft®** for their generosity in funding the technical development of the platform and making it freely available to all!





THE END

THANK YOU FOR YOUR
ATTENTION!